PERSEPHONE: Bonus Pod
from OncoPharm Hosted by John Bossaer
The release of ASCO's 2018 annual abstracts resulted in widespread media coverage of PERSEPHONE, the largest trial yet investigating 6 vs. 12 months of adjuvant trastuzumab in breast cancer. We get into the history of adjuvant trastuzumab studies and what to watch for going forward.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 13 minutes long.
When was this OncoPharm episode published?
This episode was published on May 19, 2018.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.